Vanguard Global Advisers
SGMT icon

Vanguard Global Advisers’s Sagimet Biosciences SGMT Stock Holding History

Vanguard Global Advisers’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Buy
21,758
+8,323
+62% +$56.6K ﹤0.01% 2568
2026
Q1 		$70.2K Buy
+13,435
New +$74.9K ﹤0.01% 2870

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Vanguard Global Advisers's SGMT Position: Q2 2026 in Review

Vanguard Global Advisers increased its Sagimet Biosciences (SGMT) stake by 62% in Q2 2026, buying an estimated $56.6K and bringing the position to 21,758 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #2568.

Vanguard Global Advisers first reported a position in SGMT in Q1 2026 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Vanguard Global Advisers held 21,758 shares of Sagimet Biosciences worth $168K as of Q2 2026.
  • Vanguard Global Advisers bought 8,323 Sagimet Biosciences shares in Q2 2026, an estimated $56.6K.
  • Sagimet Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2568 holding.
  • Vanguard Global Advisers first reported a position in Sagimet Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.